{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002841","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.295831+00:00","generated_at":"2026-05-28T03:51:09.662537+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Century Therapeutics reports preliminary Q4 2024 cash of ~$220M","bullets":["As of Dec 31, 2024, cash, cash equivalents and investments approx $220M.","Preliminary, unaudited; subject to change upon completion of year-end closing procedures.","Full year 2024 financial results to be included in upcoming Form 10-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002841","json":"https://secwatch.observer/filing/0001104659-25-002841.json","markdown":"https://secwatch.observer/filing/0001104659-25-002841.md","text":"https://secwatch.observer/filing/0001104659-25-002841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925002841/0001104659-25-002841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925002841/tm253008d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:51:09.662537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}